NeuroMab™ Anti-TLR4/MD-2 BBB Shuttle Antibody(NRZP-1022-ZP2662)

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Humanized

Applications

FC; ELISA; Neut; In Vitro; In Vivo

Relevant Diseases

Alzheimer's Disease; Parkinson's Disease; Ischemic Stroke; Multiple Sclerosis; Neuroinflammation

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

CD284

Official Name

TLR4

Full Name

Toll-like receptor 4

Alternative Names

TLR4; Toll-like receptor 4

Product Pictures

Inhib

Fig.1 is a graph depicting the binding of a murine monoclonal antibody, referred to here in as “7E3”, to the TLR4/MD-2 complex.

Specificity of binding is shown by flow cytometry using mock transfected or TLR4/MD-2 transfected cells.

Inhib

Fig.2 is a graph depicting inhibition of lipopolysaccharide (LPS)-induced IL-8 production in TLR4/MD-2 transfected HEK 293 cells by the monoclonal antibody mu7E3.

Specificity of binding is shown by flow cytometry using mock transfected or TLR4/MD-2 transfected cells.

Inhib

Fig.3 depicting inhibition of LPS-induced IL-6 production in human whole blood by the monoclonal antibody mu7E3.

Specificity of binding is shown by flow cytometry using mock transfected or TLR4/MD-2 transfected cells.

Inhib

Fig.4 is a series of graphs depicting the specificity of the mu7E3 monoclonal antibody for the TLR4/MD-2 complex.

The specificity of the mu7E3 antibody is shown by flow cytometry analysis of HEK 293 cells transiently transfected with either mock vector (Panel A), human TLR4 (Panel B), human TLR4 and human MD-2 (Panel C), rabbit TLR4 and rabbit MD-2 (Panel D).

Inhib

Fig.5 is a graph illustrating that the VH and VL nucleotide sequence of mu7E3 expressed as a chimeric MAb (“chimeric 7E3”) is capable of binding specifically to the human TLR4/MD-2 complex on the surface of transfected CHO cells.

Inhib

Fig.6 is a graph depicting inhibition of lipopolysaccharide (LPS)-induced IL-8 production in TLR4/MD-2 transfected HEK 293 cells by the chimeric 7E3 MAb.

Cells were incubated with chimeric 7E3 or an isotype matched MAb control at the indicated concentrations and subsequently incubated with LPS (15 ng/ml). IL-8 levels were assessed 16 hours post LPS-treatment.

Publications